drugset / Trial / NCT01209026

Corrected QT (QTc) Study With Flucticasone Furoate and GW642444

NCT01209026

Phase 1 Completed 85 enrolled GlaxoSmithKline
RandomizedCrossoverTriple-blindTreatment

Summary

A randomised, placebo controlled thorough QTc study to evaluate the effect of repeat dose FF/GW642444M combination, with moxifloxacin as a positive control, on the QTc interval in healthy male and female subjects. Key assessments will include 12- lead electrocardiogram (ECG) and pharmacokinetic (PK) parameters, along with safety being assessed by blood pressure, heart rate, clinical laboratory safety tests, and collection of adverse events.

Timeline

Start
2010-06-23
Primary completion
2011-01-04
Completion
2011-01-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Furoate Other / unclassified 200 ug Inhaled
Subject Fluticasone Furoate Other / unclassified 800 ug Inhaled
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject Vilanterol Other / unclassified 25 ug Inhaled
Subject Vilanterol Other / unclassified 100 ug Inhaled

Indications